Three promising new treatments for serious health conditions have been given special recognition in the UK, which will help speed up their development and potential availability for patients. The Medicines and Healthcare products Regulatory Agency (MHRA) has awarded ‘Innovation Passports’ to these experimental medicines. This designation allows the developers to work closely with regulators, the National Health Service (NHS), and health technology assessment groups through the UK’s Innovative Licensing and Access Pathway (ILAP). The goal is to reduce risks in the development process and get these treatments to patients sooner by encouraging collaboration across the UK healthcare system.
The three treatments are for conditions with few or no effective options currently available. The first is brezosiran, made by Alnylam, designed to treat Huntington’s disease—a condition that causes brain cells to break down over time. The second is BGB-58067, developed by BeOne Medicines, which targets non-small cell lung cancer (NSCLC), the most common type of lung cancer. The third is diranersen, created by Biogen, aimed at treating early-stage Alzheimer’s disease, which affects memory and thinking.
These medicines are still in the testing phase, and their future availability will depend on whether they are proven to be safe, effective, and beneficial for patients. The MHRA’s Chief Medical and Scientific Officer, Professor Jacob George, shared his thoughts on this initiative: ‘The Innovative Licensing and Access Pathway is a unique approach in the world that aims to get life-changing new medicines and medical devices to patients faster.’ John Spoors, from the National Institute for Health and Care Excellence (NICE), added: ‘We’re excited to use ILAP to work with medicine developers and others in the healthcare system to gather important evidence and address key issues early, which will help guide future evaluations and patient access.’
If you’re interested in applying for an Innovation Passport for a new medicine, the next round of applications opened today (November 9, 2026) and will close on February 11, 2027.